- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
- Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.
Pelthos Therapeutics Commercializes ZELSUVMI with Major Formulary Access Updates
What happened
Pelthos Therapeutics announced the commercialization of ZELSUVMI, a topical gel formulation. The company secured an agreement with a major Pharmacy Benefit Manager (PBM) that covers 24 million lives. Furthermore, a regional health plan was added, which covers approximately 3 million lives. These updates bring the total formulary coverage for ZELSUVMI to 127 million lives, representing 69% of commercially covered lives, alongside strong Medicaid coverage of over 70 million lives.
From manilatimes.net
Why it matters
The expansion of formulary coverage significantly increases the market access for ZELSUVMI. The company stated that expanding patient access has been a top priority since the product launch in July.
Ligand Pharmaceuticals acquired a 56% stake in Pelthos Therapeutics Inc. and secured royalty rights on ZELSUVMI sales. The company also formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
From manilatimes.net
Who's involved
- ApiApi (company) — company in Gifu, Japan
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ApiSpeculative
Increased market coverage might drive up sales volume, leading to higher production orders for Api.